A novel immune‑related RNA‑binding proteins signature to predict survival and therapeutic responses in prostate cancer

• Zicheng Wang ^[1] ; Yifei Zhang ^[1] ; Changqin Jiang ^[1] ; Binbin Gong ^[1]
  1. [1] First Affiliated Hospital of Anhui Medical University

     First Affiliated Hospital of Anhui Medical University

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 7, 2022, págs. 1381-1394
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Background The present study aims to identify immune-related RBPs signature to predict prognosis and therapy response in prostate cancer.

    Methods Differentially expressed RBPs were compared and visualized using R packages. Immune-related RBPs were selected by Pearson correlation analysis. The prognostic immune-related RBPs were identified using the Kaplan–Meier method and LASSO regression. A multivariable Cox regression model was used to construct immune-related RBPs signature.

    Results We constructed a prognostic predictive risk model of prostate cancer containing ten immune-related RBP genes.

    We found that high-risk prostate cancer patients presented poorer prognosis, higher tumor immune cell infiltration, higher rates of genomic alterations, and were more sensitive to targeted and immunotherapy than the low-risk group.

    Conclusions The immune-related RBPs’ signature is an independent prognostic marker that could help screen patients with advanced prostate cancer who are better suited for targeted and immunotherapy.